-
WAIT FOR SUGGESTIONS BY CATEGORY
OR CONTINUE TYPING IN YOUR KEYWORDSENTER ONE OR MULTIPLE KEYWORDS &
PRESS THE SEARCH BUTTON -
-
Search
-
Favorites
-
Advanced Minimize
-
-
-
-
Clear
- Our goal is to share knowledge regarding the world of haematology.
- With our conferences, we connect professionals all around the world.
- With this platform, we allow everyone to relive the talks and discussions of our events for free!
Welcome to the ESH eLearning Center!
ESH believes it is very important to allow specialists to gain new knowledge, competencies, and skills or to brush up on acquired ones at a time and place of their choosing.
The ESH eLearning platform comprises freely accessible:
→ on-demand components from ESH Conferences (slide bank, video presentations/ webcast, and discussions) ; whether you cannot attend live events because of time, mobility, financial or other restraints, or you simply wish to review content presented at a session you attended
→ as well as quizzes, learning tools, interviews, abstracts, documents and articles.
Stay updated:
→ Sign up for ESH Newsletter
- September 26-28, 2024: ESH-iCMLf 26th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy
- October 4-6, 2024: 7th Translational Research Conference: Multiple Myeloma
- November 1-3, 2024: 4th How to Diagnose and Treat Lymphoma
- Click to discover all the other upcoming ESH conferences
ESH provides a diverse portfolio of leading-edge scientific, translational research and clinically oriented meetings at which outstanding international faculties actively inform, mentor and interact face to face with practicing biologists and clinicians from across the world.
→ Ample time is deliberately provided for in-depth scientific discussion and interaction.
→ Registered participants further benefit from a variety of opportunities for informal scientific interaction with the world’s leading experts in their field, including during small Meet the Expert sessions and Mentored Posters Walks.
→ ESH conference delegates are invited to submit abstracts. Selected abstracts are presented as brief oral communications or posters.
ESH upcoming agenda comprises:
- Scientific Workshops:
→ organized in rapidly evolving scientific fields
- Translational Research Conferences:
→ disease-specific
→ focus on leading-edge basic, clinical and therapeutic research and future perspectives.
→ the presentation of unpublished data is encouraged.
- “How to Diagnose and Treat” Conferences:
→ disease-specific
→ emphasize clinical management, including future perspectives
→ use case-based lectures to stimulate interaction
- Leukaemias
- Myelomas
- Immune therapies and others…
- Find all our open content without logging-in
- Chairs : Chiara Bonini, Michael Hudecek, Stanley Riddell
- September 13-15, 2024 - Malahide (Dublin), Ireland
- #ESHIMMUNE2024
SCIENTIFIC TOPICS:
- Clinical development of CAR-T cell therapy
- Emerging targets for cell therapy
- Receptor engineering for tumor therapy
- Gene editing to enhance efficacy
- Novel cell types and sources – beyond autologous
- Engineering immune cells in vivo
- Correlative analyses of response and resistance
- Overcoming barriers to improve response
- The future of engineered cell therapy
FACULTY MEMBERS:
Jennifer Adair (Seattle), Larry Bacon (Dublin), Adi Barzel (Tel Aviv), Halvard Bönig (Frankfurt), Chiara Bonini (Milan), Christian Buchholz (Langen), Dirk Busch (Munich), Giulia Casorati (Milan), Aude Chapuis (Seattle), Robert Chiesa (London), Matteo Doglio (Milan), Stephen Gottschalk (Memphis), Dominic Grün (Würzburg), Michael Hudecek (Würzburg), Johannes Huppa (Berlin), Michael Jensen (Seattle), Shin Kaneko (Kyoto), Maik Luu (Würzburg), Marcela Maus (Boston), Michael O'Dwyer (Galway), Karl Petri (Würzburg), Alessia Potenza (Milan), Leo Rasche (Würzburg), Stan Riddell (Seattle), Claire Roddie (London), Marco Ruella (Philadelphia)
About the Conference:
The ESH 3rd Translational Research Conference on IMMUNE & CELLULAR THERAPIES: Focus on Advanced Gene-Engineered Immune Cells proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field.
It is open to an international audience of biologists and clinicians, including those still in-training. This translational research conference will bring together biologists and clinicians with an interest in immune & cellular therapies with a focus on advanced gene-engineered immune cells.
New data will be presented and spirited debates on how to best to apply these insights to the future of immune & cellular therapies are expected.
- Chairs : Jean-Jacques Kiladjian, Ross Levine, Jyoti Nangalia
- April 26-28, 2024 - Mandelieu-La Napoule, France
- #ESHMPN2024
On-demand programme freely available after login.
SCIENTIFIC TOPICS:
- Molecular pathogenesis of MPNs
- Novel MPN therapeutics targets
- MPN clonal evolution
- MPN models and pathogenesis/therapeutic studies
- New therapies and challenges in the management of MPN
- Update on therapeutic approaches in MPN
- Update in MPN diagnostics
- CALR Mutations in MPN Pathogenesis and Therapy
- Polycythemias
FACULTY MEMBERS:
Lionel Adès (Paris), Prithviraj Bose (Houston), Grant Challen (St Louis), Edwin Chen (Canterbury), Shannon E. Elf (Salt Lake City), Angela Fleischman (Irvine), Betty Gardie (Nantes), Stéphane Giraudier (Paris), Ana Godfrey (Cambridge), Tony Green (Cambridge), Claire Harrison (London), Ronald Hoffman (New York), Gerwin Huls (Groningen), Chloé James (Bordeaux), Jean-Jacques Kiladjian (Paris), Ross Levine (New York), Damien Luque Paz (Angers), John Mascarenhas (New York), Adam Mead (Oxford), Ruben Mesa (Charlotte), Ann Mullaly (London), Jyoti Nangalia (Cambridge), Isabelle Plo (Villejuif), Bethan Psaila (Oxford), Raajit Rampal (New York), Andreas Reiter (Mannheim), Dan Royston (Oxford), Alessandro Vannucchi (Florence)
ABOUT THE CONFERENCE:
New insights into the molecular pathogenesis, classification, and management of patients with Myeloproliferative Neoplasms (MPN) have arisen at increasing pace during the past years. This International Conference brings together scientists and clinicians to present and discuss new data on the cellular and molecular biology of these disorders as well as their diagnosis and treatment.
- Chairs : Pierre Fenaux, Katharina Götze, Mikkael Sekeres
- April 12-14, 2024 - Budapest, Hungary
- #ESHMDS2024
On-demand programme freely available after login.
SCIENTIFIC TOPICS:
- The sinister origins of MDS
- The interplay between MDS, inflammatory, and immune abnormalities
- What’s in a name? Classifying MDS
- New tools to explore MDS
- Special populations
- Treatment of lower-risk MDS
- Treatment of higher-risk MDS
- Transplantation
- Clinical trials in MDS/CMML: cooperative groups
FACULTY MEMBERS:
Lionel Adès (Paris), Didier Blaise (Marseille), Rena Buckstein (Toronto), Maria Diez Campelo (Salamanca), Pierre Fenaux (Paris), Michaela Fontenay (Paris), Guillermo Garcia-Manero (Houston), Aristoteles Giagounidis (Düsseldorf), Katharina Götze (Munich), Claudia Haferlach (Munich), Torsten Haferlach (Munich), Eva Hellström-Lindberg (Stockholm), Shahram Kordasti (London), Jaroslaw Maciejewski (Cleveland), Carsten Marr (Munich), Klaus Metzeler (Leipzig), Aziz Nazha (New Jersey), Valeria Santini (Florence), Marie Sebert (Paris), Mikkael Sekeres (Miami), Dorothée Selimoglu-Bluet (Paris), Amer Zeidan (New Haven)
ABOUT THE CONFERENCE:
#ESHMDS2024 proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field. It is open to an international audience of biologists and clinicians, including those still in-training. This translational research conference will bring together biologists and clinicians with an interest in Myelodysplastic Syndromes (MDS) in order to explore the most recent advances in the understanding of the pathogenesis and clinical behavior of the disease.
- Chairs: Jennifer Brown, Paolo Ghia, Michael Hallek
- March 8-10, 2024 - Vienna, Austria
- #ESHCLL2024
On-demand programme freely available after login.
SCIENTIFIC TOPICS:
- CLL disease progression
- Richters syndrome
- Biomarkers: where do we stand?
- Targeting the microenvironment in CLL
- What is the best time-limited therapy
- BTK inhibitors
- Small molecule resistance
- Next generation therapies
- The future: other targets
FACULTY MEMBERS:
Rafet Basar (Houston), James Blachly (Columbus), Jennifer Brown (Boston), Elias Campo (Barcelona), Matthew Davids (Boston), Barbara Eichhorst (Cologne), Toby Eyre (Oxford), Lukas Frenzel (Cologne), Richard Furman (New York), Paolo Ghia (Milan), Michael Hallek (Cologne), Arnon Kater (Amsterdam), Hien Nguyen (Cologne), Carsten Niemann (Copenhagen), Sarka Pospilova (Brno), Andy Rawstron (Leeds), Pauline Robbe (Oxford), Martina Seiffert (Heidelberg), Tanya Siddiqi (Duarte), Susan Slager (Rochester), Kostas Stamatopoulos (Thessaloniki), Justin Taylor (Miami), Elisa Ten Hacken (New York), William Wierda (Houston), Adrian Wiestner (Bethesda), Jennifer Woyach (Columbus)
ABOUT THE CONFERENCE:
#ESHCLL2024 proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field. It is open to an international audience of biologists and clinicians, including those still in-training. This translational research conference will bring together biologists and clinicians with an interest in Chronic Lymphocytic Leukaemia (CLL) in order to explore the most recent advances in the understanding of the pathogenesis and clinical behaviour of the disease.
- Chairs: Hervé Dombret, Gert Ossenkoppele, Christoph Röllig, Wendy Stock
- March 1-3, 2024 - Stockholm, Sweden
- #ESHAL2024
On-demand programme freely available after login.
SCIENTIFIC TOPICS:
- Diagnosis and treatment of rare diseases
- Novel treatments
- Dilemmas in AML
- Debate: MRD conversion before alloSCT
- Innovative trial designs to accelerate advances in leukaemia
- Immunotherapy in AML and ALL
- VenAza or intensive chemo as 1L treatment before allo HCT
- Debate: Transplant is no longer first line approach to Ph+ ALL
- Leukaemia treatment challenges
- Clonal haematopoiesis and germline predisposition
FACULTY MEMBERS:
Lionel Ades (Paris), Lucie Biard (Paris), Nicolas Boissel (Paris), Yves Chalandon (Geneva), Sabina Chiaretti (Rome), Charlie Craddock (Birmingham), Hervé Dombret (Paris), Michael Drazer (Chicago), Jordi Esteve (Barcelona), Nicola Gökbuget (Frankfurt), Chris Hourigan (Bethesda), Gerwin Huls (Groningen), Andrew Lane (Boston), Mark Litzow (Rochester), Lori Muffly (Stanford), Kristen O’Dwyer (Rochester), Etan Orgel (Los Angeles), Gert Ossenkoppele (Amsterdam), Megan Othus (Seattle), Alexander Perl (Philadelphia), Keith Pratz (Philadelphia), Marc Raaijmakers (Rotterdam), Christoph Röllig (Dresden), David Sallman (Tampa), Caner Saygin (Chicago), Judith Schaffrath (Dresden), Marie Sebert (Paris), Wendy Stock (Chicago), Richard Stone (Boston), Marion Subklewe (Munich), Adriano Venditti (Rome), Eunice Wang (Buffalo), Andrew Wei (Melbourne), Matthew J. Wieduwilt (Oklahoma City), Agnieszka Wierzbowska (Lodz), Daniel Wolff (Regensburg)
On-demand programme supported by Daiichi*
*ESH Conference programmes are developed in strict scientific independence with no input from corporate sponsors.
ABOUT THE CONFERENCE:
The programme of this conference includes genomic analysis and cutting-edge technics in routine diagnosis, targeted therapies and standard of care treatments allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes.
What's new
By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).
USER TERMS AND CONDITIONS | PRIVACY POLICY
Accept Terms & all Cookies
MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.
Performance Cookies
Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.
Google Analytics and Google Tag Manager embedded tracking functionalities are used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG's features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.